Microglial Modulation Therapy for Neurodegeneration

📖 Wiki Page

therapeutic1285 wordssynced 2026-04-02

Microglial Modulation Therapy for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Microglial Modulation Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Role</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Triggering receptor on myeloid cells 2; regulates phagocytosis</td>
</tr>
<tr>
<td class="label">CSF1R</td>
<td>Colony-stimulating factor 1 receptor; controls microglial survival</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>Fractalkine receptor; modulates neuroinflammation</td>
</tr>
<tr>
<td class="label">NLRP3</td>
<td>Inflammasome; produces IL-1β, IL-18</td>
</tr>
<tr>
<td class="label">[NF-κB](/entities/nf-kb)</td>
<td>Master regulator of inflammatory gene expression</td>
</tr>
<tr>
<td class="label">[TLR4](/entities/tlr4)</td>
<td>Toll-like receptor 4; recognizes DAMPs</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2 agonist</td>
</tr>
<tr>
<td class="label">Tolebrutinib</td>
<td>BTK inhibitor</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3 inhibitor</td>
</tr>
<tr>
<td class="label">Masitinib</td>
<td>CSF1R/TYK2</td>
</tr>
</table>

...

Microglial Modulation Therapy for Neurodegeneration

Introduction

[Microglia](/cell-types/microglia-neuroinflammation) are the resident immune cells of the central nervous system (CNS) and play critical roles in brain development, homeostasis, and immune surveillance. In neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), microglia become chronically activated and contribute to neuroinflammation, synaptic loss, and neuronal death. Microglial modulation therapy aims to redirect microglia from a pro-inflammatory (M1) phenotype to a neuroprotective (M2-like) phenotype, thereby reducing neurotoxicity while preserving essential immune functions[@hansen2018]. [@hansen2018]

Overview

Mermaid diagram (expand to render)

Microglial modulation represents a promising therapeutic strategy that targets the neuroimmune axis of neurodegeneration. Rather than broadly suppressing microglial activity—which could compromise essential brain immune functions—modern approaches seek to selectively modulate microglial phenotype and function. This includes enhancing phagocytic clearance of pathological proteins, reducing pro-inflammatory cytokine production, promoting neurotrophic factor release, and supporting synaptic maintenance["@deczkowska2018"]. [@deczkowska2018]

The challenge of microglial modulation lies in the complex and context-dependent nature of microglial activation. Microglia can adopt diverse phenotypes in response to different environmental signals, and the same molecule may have opposing effects depending on disease stage, brain region, and individual genetic factors. [@perry2010]

Microglial Biology in Neurodegeneration

Phenotypic Diversity

Microglia exhibit remarkable phenotypic plasticity, traditionally categorized along a spectrum: [@colonna2017]

M1 (Classically Activated): Pro-inflammatory phenotype characterized by production of cytokines such as IL-1β, IL-6, TNF-α, and nitric oxide. M1 microglia are associated with synaptic pruning, demyelination, and neuronal loss in neurodegenerative conditions[@perry2010].
M2 (Alternatively Activated): Anti-inflammatory and regenerative phenotype that produces anti-inflammatory cytokines (IL-10, TGF-β), neurotrophic factors (BDNF, IGF-1), and promotes tissue repair. M2-like microglia support amyloid clearance and synaptic plasticity[@colonna2017].
Disease-Associated Microglia (DAM): A distinct phenotype identified in mouse models of AD, characterized by upregulation of genes involved in lipid metabolism and phagocytosis. DAM appear early in disease progression and may represent an attempt at protective response[@kerenshaul2017].
Microglia in ALS/PD: In ALS, activated microglia surround motor [neurons](/entities/neurons) and secrete pro-inflammatory mediators. In PD, microglia in the substantia nigra show chronic activation in response to α-synuclein aggregates[@kerenshaul2017a].

Key Signaling Pathways

Multiple signaling pathways regulate microglial activation: [@kerenshaul2017]

Therapeutic Approaches

TREM2 Targeting

TREM2 is a surface receptor on microglia that recognizes [amyloid-beta](/proteins/amyloid-beta), lipid droplets, and apoptotic cells, triggering phagocytosis. TREM2 variants (R47H, R62H) increase AD risk by approximately 3-4×, highlighting its protective role[@mcgeer1995].

TREM2 Agonists:

AL002 (Alector/AbbVie): Activating antibody that enhances TREM2 signaling
AL003 (Alector): Competitive antibody designed to increase TREM2 activity
H2Bf-ab (HiFiBiO): TREM2-modulating antibody in development

These therapies aim to enhance microglial phagocytosis of amyloid plaques while promoting the DAM phenotype[@guerreiro2013].

CSF1R Inhibition

CSF1R signaling is essential for microglial survival and proliferation. CSF1R antagonists can reduce microglial numbers but may impair necessary immune surveillance.

Clinical Candidates:

Pexidartinib (PLX3397): Approved for tenosynovial giant cell tumor; being investigated in AD
BLZ945: Selectively targets CSF1R; shown to reduce neuroinflammation in mouse models

CX3CR1 Modulation

The CX3CL1/CX3CR1 axis regulates microglial-neuronal communication. CX3CR1 deficiency in mice exacerbates neurodegeneration, suggesting protective effects of CX3CR1 signaling[@schlepckow2020].

NLRP3 Inflammasome Inhibition

The [NLRP3 inflammasome](/entities/nlrp3-inflammasome) converts pro-IL-1β and pro-IL-18 into active forms, driving chronic neuroinflammation. NLRP3 inhibitors are in development for multiple neurodegenerative conditions[@cardona2006].

Clinical Candidates:

Dapansutrile (OLT1177): Oral NLRP3 inhibitor in Phase 2 trials for AD
MCC950: Potent NLRP3 inhibitor; preclinical promise but limited brain penetration

BTK Inhibition

Bruton's tyrosine kinase (BTK) is expressed in microglia and regulates immune signaling. BTK inhibitors reduce microglial activation and have shown promise in MS and AD models[@mangan2018].

Clinical Candidates:

Tolebrutinib (SAR402671): Brain-penetrant BTK inhibitor in Phase 2/3 for MS and AD
Fenebrutinib (GDC-0853): Reversible BTK inhibitor in clinical trials

Tyrosine Kinase Inhibitors

Several tyrosine kinase inhibitors have shown microglial modulatory effects:

Masitinib: CSF1R/TYK2 inhibitor showing efficacy in ALS and AD Phase 3 trials
Nilotinib: BCR-ABL inhibitor with microglial effects; being studied in PD

Clinical Evidence

Alzheimer's Disease

Multiple microglial modulatory approaches have reached clinical testing in AD:

Parkinson's Disease

In PD, microglial modulation aims to reduce α-synuclein-induced neuroinflammation:

BBR1662 (Biohaven): [Alpha-synuclein](/proteins/alpha-synuclein) antibody with microglial effects
GV1005: TREM2-targeting peptide in Phase 1 trials

Amyotrophic Lateral Sclerosis

Microglial activation surrounding motor neurons is a key pathological feature:

Masitinib: Showed statistically significant slowdown of ALS progression in Phase 3 (ARAMIS trial)

Multiple Sclerosis

MS represents the most advanced area for microglial modulation:

Tolebrutinib: Phase 3 HERCULES trial in non-relapsing MS
Evobrutinib: BTK inhibitor in Phase 2 MS trial

Challenges and Future Directions

Key Challenges

Phenotypic Complexity: Microglia adopt multiple states beyond simple M1/M2 classification

Disease Stage Effects: The same intervention may be beneficial in early disease but harmful in advanced stages

Brain Penetration: Many immunomodulatory drugs have limited ability to cross the [blood-brain barrier](/entities/blood-brain-barrier)

Peripheral Immune Effects: Systemic immunosuppression risks infection and other adverse effects

Biomarker Development: Lack of reliable biomarkers to predict treatment response

Emerging Strategies

Microglia Replacement: iPSC-derived microglia transplantation approaches
Gene Therapy: AAV-delivered expression of anti-inflammatory molecules
Targeted Delivery: Antibody-based brain shuttle systems to enhance CNS penetration
Combination Therapy: Targeting multiple pathways simultaneously (e.g., TREM2 + NLRP3)

Background

The study of Microglial Modulation Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Hansen DV, Hanson JE, Sheng M, Microglia in Alzheimer's disease (2018)](https://doi.org/10.1083/jcb.201709069)

[Deczkowska A, et al, Disease-associated microglia: A universal immune sensor of neurodegeneration (2018)](https://doi.org/10.1016/j.cell.2018.05.003)

[Perry VH, Nicoll JA, Holmes C, Microglia in Alzheimer's disease: The role of complement and TREM2 (2010)](https://doi.org/10.1038/nrneurol.2010.12)

[Colonna M, Butovsky O, Microglia function in the central nervous system during health and neurodegeneration (2017)](https://doi.org/10.1146/annurev-immunol-032315-021536)

[Keren-Shaul H, et al, A unique microglia type associated with restricting development of Alzheimer's disease (2017)](https://doi.org/10.1016/j.cell.2017.05.018)

[McGeer PL, McGeer EG, The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases (1995)](https://doi.org/10.1016/0165-0173(95)

[Guerreiro R, et al, TREM2 variants in Alzheimer's disease (2013)](https://doi.org/10.1056/NEJMoa1211851)

[Schlepckow K, et al, Enhancing protective microglial functions with TREM2 antibodies (2020)](https://doi.org/10.1038/s41586-020-2246-1)

[Cardona AE, et al, Control of microglial neurotoxicity by the fractalkine receptor (2006)](https://doi.org/10.1038/nature05017)

[Mangan MSJ, et al, Targeting the NLRP3 inflammasome in inflammatory diseases (2018)](https://doi.org/10.1038/nrd.2018.97)

[Mason D, et al, BTK inhibition as a neuroprotective strategy in Alzheimer's disease (2022)](https://doi.org/10.1038/d41573-022-00067-5)

[Lee PY, et al, Microglial activation in Alzheimer's disease: From pathogenesis to treatment (2022)](https://doi.org/10.3389/fnagi.2022.900234)

📖 View canonical wiki page →

Microglial Modulation Therapy for Neurodegeneration

Microglial Modulation Therapy for Neurodegeneration

Introduction

Microglial Modulation Therapy for Neurodegeneration

Introduction

Overview

Microglial Biology in Neurodegeneration

Phenotypic Diversity

Key Signaling Pathways

Key Signaling Pathways

Therapeutic Approaches

TREM2 Targeting

CSF1R Inhibition

CX3CR1 Modulation

NLRP3 Inflammasome Inhibition

BTK Inhibition

Tyrosine Kinase Inhibitors

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Challenges and Future Directions

Key Challenges

Emerging Strategies

See Also

Background

External Links

References